Host-Cell Proteins: What Purification Has to Remove, and How It Is Measured
Host-cell proteins, usually shortened to HCPs, are the proteins made by the production organism itself — the bacterium, yeast or mammalian cell line used to express a recombinant product. They are process-related impurities derived from the host organism and have to be controlled to keep product quality and safety adequate [5]. Reducing them to an acceptably low level is a major focus of any therapeutic protein purification process [7].
The difficulty is that "HCP" is not one substance. Recent proteomic analysis has shown how diverse this class of impurity is, potentially thousands of protein species [1]. Though often referred to as a single impurity, HCPs comprise a variety of species with diverse abundance, size, function and composition, and their clearance varies from cell line to cell line, product to product, and batch to batch [4].
Where they come from
In mammalian culture, HCPs are both secreted by living cells and released from lysed cells, accumulating extracellularly over the course of the culture [2]. The amount depends on how the culture is run. In a study of an antibody-producing recombinant CHO cell line, more HCPs were identified and quantified in fed-batch culture (2,145 proteins identified, 1,673 quantified) than in batch culture (1,934 identified, 1,486 quantified), because fed-batch reached a higher cell concentration and ran longer [2].
Raising upstream titre does not make the downstream job easier. Higher upstream titres have created more complex impurity profiles, in both mass and composition, demanding higher separation capacity and selectivity in downstream processing, and shifting cost from the upstream to the downstream side of the process [3].
Bacterial hosts carry their own signature. In an Escherichia coli process, host-cell proteins were identified at different purification steps by HPLC fractionation, SDS-PAGE and tryptic peptide mapping with online LC-MS, and bacterial alkaline phosphatase (BAP) was the most abundant host-cell protein at several purification steps [7].
Not all HCPs behave the same in a column
One useful way to think about removal is to sort HCPs by how far their physicochemical properties sit from the product's. In that scheme, "Ugly" HCPs have a MW above 15 kDa and a pI between 7.30 and 9.30; "Bad" HCPs have a MW above 15 kDa with a pI of 4.75–7.30 or 9.30–10.00; and "Good" HCPs are below 15 kDa with a pI below 4.75 or above 10.00, because their properties differ significantly from the product [3]. Species that are especially difficult to remove and persist through downstream processing have to be evaluated by their ability to be separated at all, and the authors stress that orthogonal analytical methods — ion exchange, hydrophobic interaction and size exclusion chromatography — are needed to evaluate the classification [3].
Improved proteomic monitoring has likewise identified a subset of "problematic" HCPs that are particularly challenging to remove at both the capture and the polishing step, and that can compromise product stability and safety even at trace concentrations [4].
Tracking clearance step by step
Knowing the total figure at the end is not the same as knowing where removal happens. Quantitative iTRAQ proteomics has been used to follow the HCP profile of an antibody-producing CHO-S cell line through a standard downstream sequence of Protein A capture followed by cation and anion exchange [6]. Samples included harvested cell culture fluid, Protein A flow-through and Protein A eluate, and then the two ion exchange steps; across the experiments 936 proteins were identified, and the data allowed estimation of the relative change of individual proteins across each purification step [6]. That is the basis on which critical HCPs can be picked out for process development [6].
Removal can also be designed into the resin. Synthetic peptide ligands screened from solid-phase peptide libraries were developed to capture a broad spectrum of CHO HCPs while binding human IgG, used as a model product, as little as possible [4]. Tetrameric and hexameric ligands with multipolar or hydrophobic/positive amino acid compositions performed best, and tetrameric multipolar ligands gave the highest ratio of HCP clearance to IgG loss — more than double that of commercial mixed-mode and anion exchange resins used for IgG polishing [4]. All the peptide resins tested bound HCPs preferentially over IgG, which points to use in flow-through or weak-partitioning mode [4].
What a residual HCP can do to the product
The reason a few species matter more than a bulk number is that some of them are enzymes that act on the product. Clustering of HCP concentration profiles in CHO culture showed that species affecting antibody quality — Lgmn, Ctsd, Gbl1 and B4galt1 — tracked with changes in aggregation, charge variants and N-glycosylation during the culture [2].
A documented case makes the point concretely. N-glycan heterogeneity is not normally expected to be a stability-indicating attribute, yet significant N-glycan degradation was seen for one monoclonal antibody under accelerated and stressed stability conditions [5]. The root cause was hexosaminidase B (HEXB), an enzyme that removes terminal N-acetylglucosamine; LC-MS-based proteomics found it enriched in the affected stability batches [5]. Enzymatic and targeted multiple-reaction-monitoring MS assays were then developed, a potential interaction between HEXB and the antibody was supported by computational modelling, and an improved bioprocess was developed that significantly reduced HEXB in the final drug substance [5]. The authors report this as the first residual HCP shown to affect the glycan profile of a formulated product [5].
Residual enzyme activity can be followed as well as mass. In the E. coli case, two assays were set up for BAP — one enzymatic, one immunological — and the purification process was shown to remove almost all BAP enzymatic activity, with monitoring running at high throughput [7].
Measuring what is left
The standard method is an ELISA built on polyclonal antibodies raised against the host cell used for production [1]. It is elegant, but the result depends entirely on the antibody serum, which sets both the assay's sensitivity and how much of the HCP spectrum it covers, and it returns one summed value — fine if every HCP component is equal in risk, unhelpful if it is not [1]. Monitoring has to demonstrate removal below the regulatory accepted level of 100 ng/mg [8].
One published workflow combines automated magnetic bead-based sample preparation with data-independent acquisition LC-MS/MS, using the same instrument setup normally used for peptide mapping, so it can be folded into existing workflows without dedicated instruments or staff; it quantifies HCPs over a broad dynamic range and allows problematic species to be monitored or tracked as bioprocess conditions change [8]. The trade-off is data volume: measuring thousands of proteins increases the data acquired proportionally, and the value only appears if that information is used to determine critical HCPs and build a better basis for risk management [1].
What to take from this
When assessing a process or a process-transfer partner, the useful questions follow directly from the evidence. Ask which HCPs were identified, not only what the total number was — the summed ELISA value hides the distribution [1]. Ask whether clearance was measured step by step across capture and polishing, as iTRAQ tracking across Protein A and ion exchange allows [6]. Ask whether any residual species has known enzymatic activity against the product, since a single enzyme has been shown to degrade glycans during storage [5]. Ask whether the upstream condition itself was examined, since culture mode and duration change how many HCPs accumulate [2], and since downstream characterisation data can be fed back to upstream to optimise media and process and reduce critical HCPs at source [3].
References
- Bracewell DG, Francis R, Smales CM. The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control — Biotechnology and bioengineering, 2015-07-14.
- Park JH, Jin JH, Lim MS, An HJ, Kim JW, Lee GM. Proteomic Analysis of Host Cell Protein Dynamics in the Culture Supernatants of Antibody-Producing CHO Cells — Scientific reports, 2017-03-10.
- Kornecki M, Mestmäcker F, Zobel-Roos S, Heikaus de Figueiredo L, Schlüter H, Strube J. Host Cell Proteins in Biologics Manufacturing: The Good, the Bad, and the Ugly — Antibodies (Basel, Switzerland), 2017-09-16.
- Lavoie RA, di Fazio A, Blackburn RK, Goshe MB, Carbonell RG, Menegatti S. Targeted Capture of Chinese Hamster Ovary Host Cell Proteins: Peptide Ligand Discovery — International journal of molecular sciences, 2019-04-08.
- Li X, An Y, Liao J, Xiao L, Swanson M, Martinez-Fonts K, Pavon JA, Sherer EC, Jawa V, Wang F, Gao X, Letarte S, Richardson DD. Identification and characterization of a residual host cell protein hexosaminidase B associated with N-glycan degradation during the stability study of a therapeutic recombinant monoclonal antibody product — Biotechnology progress, 2021-03-12.
- Chiverton LM, Evans C, Pandhal J, Landels AR, Rees BJ, Levison PR, Wright PC, Smales CM. Quantitative definition and monitoring of the host cell protein proteome using iTRAQ - a study of an industrial mAb producing CHO-S cell line — Biotechnology journal, 2016-06-22.
- Bomans K, Lang A, Roedl V, Adolf L, Kyriosoglou K, Diepold K, Eberl G, Mølhøj M, Strauss U, Schmalz C, Vogel R, Reusch D, Wegele H, Wiedmann M, Bulau P. Identification and monitoring of host cell proteins by mass spectrometry combined with high performance immunochemistry testing — PloS one, 2013-11-27.
- Strasser L, Oliviero G, Jakes C, Zaborowska I, Floris P, Ribeiro da Silva M, Füssl F, Carillo S, Bones J. Detection and quantitation of host cell proteins in monoclonal antibody drug products using automated sample preparation and data-independent acquisition LC-MS/MS — Journal of pharmaceutical analysis, 2021-05-20.

